.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Integrating Ocular Toxicity Management into Routine Care for Solid Tumor Patients Receiving Treatment with ADCs

Panelists discuss the role of ADCs in solid tumor care, explore the ocular adverse events associated with these agents, and discuss best practices for monitoring and managing ocular toxicities in clinical practice.

EP. 1: Antibody Drug Conjugates (ADCs) for Treatment of Solid Tumors

December 16th 2025

Experts discuss the integration of ocular toxicity management in solid tumor care, focusing on antibody-drug conjugates and their impact on treatment.

EP. 2: Classifying ADC Associated Ocular Toxicities and Evaluating Them in Everyday Practice

December 16th 2025

Ocular toxicities from cancer treatments present complexities; understanding symptoms and timely ophthalmology involvement is crucial for effective management.